Clinical Scorecard: The Role of Digital Pathology and Lipid Droplet Dimensions in Explaining Differences Between Histological and MRI Assessments in Steatotic Liver Disease

At a Glance

Key Highlights

• Histological steatosis grading relies on subjective estimation of large lipid droplets displacing hepatocyte nuclei, often overlooking tiny and small LDs.
• MRI-proton density fat fraction (PDFF) is a non-invasive, sensitive, and accurate method for quantifying liver fat and monitoring treatment response.
• Digital image analysis (DIA) enables objective quantification of LD size distribution, potentially explaining discrepancies between histology and MRI-PDFF steatosis grades.

Guideline-Based Recommendations

Diagnosis

• Use liver biopsy with histological evaluation as the current standard for hepatic steatosis assessment, focusing on large LDs for grading.
• Employ MRI-PDFF for non-invasive quantification and longitudinal monitoring of liver fat content.
• Incorporate digital pathology and DIA to objectively quantify LD size distribution for research and validation purposes.

Management

• Monitor treatment response using MRI-PDFF, considering a ≥30% PDFF reduction as predictive of improved MASLD activity score and fibrosis regression.
• Recognize limitations of histological grading due to sampling variability and LD size detection biases.

Monitoring & Follow-up

• Use MRI-PDFF for longitudinal assessment of steatosis changes during interventions.
• Consider DIA metrics in research settings to better understand steatosis burden and treatment effects.

Risks

• Potential underestimation of steatosis severity by histology due to overlooking tiny and small LDs.
• Sampling errors and tissue processing artifacts affecting histological assessment accuracy.
• MRI contraindications and imaging artifacts limiting applicability in some patients.

Patient & Prescribing Data

Adults with chronic liver disease undergoing liver biopsy and MRI evaluation

MRI-PDFF reductions correlate with histological improvements and fibrosis regression, supporting its use as a treatment endpoint in clinical trials.

Clinical Best Practices

• Ensure liver biopsy samples meet quality criteria (≥15 mm length, ≥6 portal tracts) for reliable histological assessment.
• Use standardized MRI protocols with consistent PDFF sequence parameters for accurate fat quantification.
• Apply DIA with adipophilin immunohistochemistry to quantify LD size distribution, especially in research contexts.
• Interpret histological steatosis grades considering the limitations of detecting small and tiny LDs.
• Integrate MRI-PDFF findings with histology and DIA data to comprehensively assess steatosis severity.

References

• Global health issue of steatotic liver disease
• Histological evaluation and limitations
• MRI-PDFF accuracy and clinical relevance
• Digital image analysis and lipid droplet quantification
• Study design and methodology